Treatment of pediatric acute lymphoblastic leukemia.

Pediatr Clin North Am 2015 Feb 18;62(1):61-73. Epub 2014 Oct 18.

Pediatric Leukemia Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, 1650 Orleans Street, CRB1 Room 2M49, Baltimore, MD 21231, USA. Electronic address:

Acute lymphoblastic leukemia (ALL) is the most common pediatric oncologic diagnosis, and advances in its treatment have led to progressive improvements in survival. The 4 main components of therapy are remission induction, consolidation, maintenance, and central nervous system-directed therapy, and usually last 2 to 3 years. Treatment intensity based on risk-based stratification is the cornerstone of treatment. Patients with features of more favorable disease are spared the more toxic effects of chemotherapy, whereas more aggressive regimens are reserved for those with higher-risk disease. Prognosis of relapsed pediatric ALL depends primarily on duration of remission and site of relapse.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pcl.2014.09.006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4366417PMC

Still can't find the full text of the article?

We can help you send a request to the authors directly.
February 2015
10 Reads

Publication Analysis

Top Keywords

lymphoblastic leukemia
8
acute lymphoblastic
8
stratification cornerstone
4
risk-based stratification
4
based risk-based
4
cornerstone treatment
4
features favorable
4
patients features
4
treatment patients
4
intensity based
4
years treatment
4
central nervous
4
maintenance central
4
consolidation maintenance
4
nervous system-directed
4
system-directed therapy
4
favorable disease
4
treatment
4
treatment intensity
4
spared toxic
4

Similar Publications